Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of GDC-6036 and GDC-1971 in advanced solid tumors
jRCT2031220195Phase 1Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of divarasib and migoprotafib in Nonhematologic neoplasms (3 cohorts), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety and Pharmacokinetics. Started Sep 2022; status: active, not recruiting.
02
Drugs
divarasibmigoprotafib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031220195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220195.